mRNA-4157/V940 + KEYTRUDA® (pembrolizumab) Met Primary Efficacy Endpoint in Ph 2b KEYNOTE-942 Trial December 19, 2022
Ph 1 Trial of E6201 + Dabrafenib initiated in Patients with CNS Metastases from BRAF V600 Mutated Metastatic Melanoma December 5, 2022
IO Biotech and Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 With KEYTRUDA in Ph 2 Trial in Patients with Resectable Tumors November 16, 2022
Eucure Biopharma Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence November 16, 2022
Voluntary Pause of Enrollment in Ongoing in ITIL-168 and ITIL-306 Trials Related to Manufacturing November 16, 2022
Data from CheckMate -76K Shows that Opdivo Reduced the Risk of Recurrence or Death by 58% vs. Placebo in Patients with Completely Resected Stage IIB/C Melanoma October 26, 2022
Adjuvant Treatment with Opdivo Demonstrated Statistically Significant Improvement in RFS in Patients with Stage IIB/C Melanoma in the CheckMate-76K Trial September 28, 2022
European Commission approves Opdualag (nivolumab + relatlimab) for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1% September 28, 2022
Positive data announced from multiple expansion cohorts of Ph 1 trial of fianlimab and Libtayo® (cemiplimab) in advanced melanoma September 13, 2022
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable CSCC Published in NEJM September 13, 2022
Enrollment initiated in Ph 2 Trial of Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma September 7, 2022
Ph 2 SCOPE trial of SCIB1 vaccine in metastatic melanoma patients expanded; additional cohort to test SCIB1 vaccine in combination with checkpoint doublet therapy June 16, 2022
